Cubist Pushes Trius Drug Forward As Cubicin Comes Up Short
This article was originally published in The Pink Sheet Daily
Executive Summary
The antibiotic drug maker is already making advantageous moves after closing one of its two most recent acquisitions, even as its highest-revenue product sees stalled growth.